Best-in-Class Masking Platform (ByonGuard™)
Many tumor-associated antigens (TAAs) targeted by antibody therapies are also present in health tissue, causing on-target off-tumor toxicity, affecting treatment safety and limiting combination options. Our innovative universal masking platform, ByonGuard, is designed to improve the therapeutic index of antibody-based therapies with no bespoke peptides needed. Preclinical data support ByonGuard masked ADC with high sub-nanomolar potency and high efficacy with safety and PK/PD studies supporting increased therapeutic index.
ByonGuard™- Highly differentiated Universal Mask with no binding peptide engineering required.
Affinity masking
✗ Antibody needs its bespoke masking peptide with unique binding profile and risk profile (immunogenicity, CMC)
✗ Masking peptide remains bound after cleavage hampering target engagement in the tumor
ByonGuard™ - Steric masking
✓ One size fits all, no bespoke peptides needed
✓ Lower risk profile vs affinity mask
✓ Faster and more simplified development, with higher probability of success
✓ Mask does not increase immunogenicity of antibody
✓ Cleavage fully restores anti-tumor potency
ByonGuard™ Masking Provides an Increased Therapeutic Window and is Efficiently Unmasked and Activated in the TME
Best-in-Class ByonGuard™ Masked Platform: Entering the Clinic and Ready for Partnering.
Byondis is developing ADCs with the novel ByonGuard masking platform, with a frontrunner at advanced preclinical stage and multiple follow-up programs at earlier preclinical stages.
Antifolate Linker-Drug Platform
Working to overcome antibody drug conjugate (ADC) resistance as therapies move into earlier treatment lines and in combination, our antifolate platform provides a differentiated and validated MOA with a payload designed to overcome systemic side effects.
Phosphonate Linker-Drug Platform (ByonBoost™)
Our ByonBoost™ phosphonate linker-drug platform is aiming to deliver a range of antibody drug conjugates (ADCs) with high compabilitlity for solid oncology and hematological malignancies.
